Perception of Anti-TNF Biosimilars among Payer Stakeholders in the United Kingdom, France, Germany, Italy, and Spain


In this article, the authors report the perception of anti-TNF biosimilars among payer stakeholders in the big-5 European countries, their rating of level of comfort with extrapolation of clinical data, quality of clinical and economic data available for novel compound evaluations and the perception of suitable target population for biosimilars.


Siva Narayanan Alessandra Franceschett Yao Lu Richard Hutchings Amanda Baskett Sam Mentzer

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now